Skip to content

Baseline Performance and Fitting Parameters for Sonova Products

Baseline Performance and Fitting Parameters for Sonova Products

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05859568
Enrollment
20
Registered
2023-05-16
Start date
2023-04-17
Completion date
2028-04-17
Last updated
2025-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ear Diseases, Hearing Disorders, Hearing Loss, Otolaryngological Disease

Brief summary

The purpose of this study is to assess the effectiveness and optimization of various FDA approved products.

Detailed description

This study uses a prospective within-subjects repeated-measures design in which each subject serves as her/his own control. The purpose of this study is to assess the effectiveness and optimization of various FDA approved hardware, signal preprocessing and processing software, fitting characteristics, and service delivery methods, such as remote support and/or tele-audiology on an expanded subject demographic. The insights gained from this study will be used to optimize listening configuration recommendations, refine audiological practice, and inform future innovations.

Interventions

DEVICEPinna-located microphone

Sound processors using a pinna-located microphone

DEVICEPinna-simulated microphone algorithm

Sound processors using a pinna-simulated algorithm

Sponsors

Advanced Bionics
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to provide Informed Consent/Assent * Adults (age +18 years) and children (8-17 years) can be enrolled in this study * If child is aged 8-17 years, an assent will be completed, and the subject must be accompanied by a parent or legal guardian for all study activities * Have the functional capability to operate the controls for the device and to comply with all directions during the study as determined by the investigator conducting the consent/baseline visit * English language proficiency as determined by the investigator

Exclusion criteria

• Have any significant medical condition that, in the opinion of any of the investigators, is likely to interfere with study procedures or likely to confound evaluation of study endpoints

Design outcomes

Primary

MeasureTime frameDescription
Speech performance in noise1 dayThe primary efficacy endpoint is recorded AzBio sentences presented from a single loud speaker at 60 dBA. The recognition scores using the pinna-located microphone in quiet and noise captured at initial visit will be compared to the AzBio sentence recognition scores using the pinna-simulated microphone. Scores are determined on a scale of 0% to 100% words correct with higher scores indicating a better outcome.

Secondary

MeasureTime frameDescription
Localization performance1 dayA secondary efficacy endpoint is a front/back localization task where filtered pink noise is presented at 60dBA from one of six speakers in a 360 degree array. Scores are generated in percent correct; the scores obtained from the pinna-located microphone will be compared to the localization scores using the pinna-simulated microphone.
Analysis of usability and preference questionnaire8 weeksSubject responses captured on a usability and preference questionnaire at the initial visit will be compared to responses on the questionnaire administered after each two-week chronic use interval. Questions will inquire about subject's ability and experience hearing and listening in different situations and wearing configuration preferences. The questions are rated on a 5-point Likert scale with varying strength, such as It was easy to verify proper microphone function with answers ranging from strongly disagree to strongly agree.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026